← FDA DRUG APPROVALS

FDA ANDA · ANDA208084

CLINDAMYCIN PHOSPHATE

Sponsor: BAXTER HLTHCARE CORP

APPLICATION
ANDA208084
TYPE
ANDA
ORIGINAL APPROVAL
2017-06-28
LATEST ACTION
2023-09-18
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINERPrescription
CLINDAMYCIN PHOSPHATE EQ 18MG BASE/ML · INJECTABLE · INJECTION
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINERPrescription
CLINDAMYCIN PHOSPHATE EQ 6MG BASE/ML · INJECTABLE · INJECTION
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINERPrescription
CLINDAMYCIN PHOSPHATE EQ 12MG BASE/ML · INJECTABLE · INJECTION

Approval history

2023-09-18Labeling · Supplement 5 · standardAP
2023-09-18Labeling · Supplement 3 · standardAP
2020-05-14Labeling · Supplement 2 · standardAP
2017-06-28UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →